Small Cell Lung Cancer Clinical Trials

Determine the safety, tolerability and maximum tolerated dose of anetumab ravtansine (BAY 94-9343) in combination with pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 in subjects with mesothelin-expressing predominantly epithelial mesothelioma or nonsquamous non-small-cell lung cancer.

To characterize the safety, tolerability, pharmacokinetics and immunogenicity of anetumab ravtansine in subjects with advanced solid cancers and with different degrees of hepatic or renal impairment

Characterize the safety, tolerability, ECG effects, pharmacokinetics and immunogenicity of anetumab ravtansine given as single agent and after inhibition of CYP3A4 and P-gp by concomitant administration of itraconazole in subjects with mesothelin-expressing advanced solid cancers

The relatively restricted C4.4a expression pattern provides a target for the selective delivery of a cytotoxic drug to C4.4.a-expressing tumor cells by means of a suitable antibody-drug conjugate. The subject population eligible for the current study will be those subjects with advanced malignancies known to express C4.4a, which are refractory ...

- This is the first study where BAY1163877 is given to humans. Impact of the study is to evaluate if patients with advanced solid cancers show advanced clinical benefit under the treatment with the pan FGFR inhibitor. Patients (all comers) will receive the study drug treatment in a dose-escalation scheme ...

In this phase I multiple dose, dose escalation study utilizing a classic 3+3 design. Sequential cohorts of patients will receive AEB1102 IV weekly at one of a series of increasing dose levels. Dose escalation will be dependent on the frequency of specific dose-limiting toxicities in the prior cohort of patients. ...

A research study is evaluating an investigational oral medication for non-small cell lung cancer (NSCLC). This research study may be an option if you: • Are at least 18 years of age • Have been diagnosed with stage IIIB or IV metastatic NSCLC • Have fully recovered from any previous ...

People with Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1are asked to participate in a research study being conducted by Montefiore Medical Center.

People with Advanced or Metastatic Nonsmall Cell Lung Cancer are asked to participate in a research study being conducted by Montefiore Medical Center.

This is a multicenter, open-label, multi-arm Phase 2 study to evaluate the efficacy and safety of single agent niraparib in patients with locally advanced and metastatic sqNSCLC and of the combination of niraparib and pembrolizumab in locally advanced and metastatic NSCLC (all histologies) patients.